Insider Transactions in Q1 2022 at Adicet Bio, Inc. (ACET)
Insider Transaction List (Q1 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 09
2022
|
Aya Jakobovits |
SELL
Open market or private sale
|
Indirect |
4,000
-0.56%
|
$56,000
$14.0 P/Share
|
|
Feb 16
2022
|
Aya Jakobovits |
SELL
Open market or private sale
|
Indirect |
4,000
-0.56%
|
$56,000
$14.83 P/Share
|
|
Feb 14
2022
|
Chen Schor President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
21,288
-12.47%
|
$298,032
$14.27 P/Share
|
|
Feb 14
2022
|
Chen Schor President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
48,000
+21.95%
|
-
|
|
Feb 14
2022
|
Brian Nicholas Harvey Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,696
-7.92%
|
$65,744
$14.27 P/Share
|
|
Feb 14
2022
|
Brian Nicholas Harvey Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+21.25%
|
-
|
|
Feb 14
2022
|
Francesco Galimi SVP & Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,533
-8.45%
|
$77,462
$14.27 P/Share
|
|
Feb 14
2022
|
Francesco Galimi SVP & Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+19.64%
|
-
|
|
Feb 14
2022
|
Blake Aftab Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,533
-9.47%
|
$77,462
$14.27 P/Share
|
|
Feb 14
2022
|
Blake Aftab Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+21.5%
|
-
|
|
Feb 14
2022
|
Don Healey Chief Technology Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,533
-9.46%
|
$77,462
$14.27 P/Share
|
|
Feb 14
2022
|
Don Healey Chief Technology Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+21.49%
|
-
|
|
Feb 09
2022
|
Aya Jakobovits |
SELL
Open market or private sale
|
Indirect |
8,000
-1.1%
|
$112,000
$14.03 P/Share
|
|
Jan 28
2022
|
Chen Schor President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
21,288
-14.78%
|
$234,168
$11.69 P/Share
|
|
Jan 28
2022
|
Chen Schor President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
48,000
+25.0%
|
-
|
|
Jan 28
2022
|
Brian Nicholas Harvey Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,696
-9.78%
|
$51,656
$11.69 P/Share
|
|
Jan 28
2022
|
Brian Nicholas Harvey Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+25.0%
|
-
|
|
Jan 28
2022
|
Blake Aftab Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,564
-11.59%
|
$61,204
$11.69 P/Share
|
|
Jan 28
2022
|
Blake Aftab Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+25.0%
|
-
|
|
Jan 28
2022
|
Don Healey Chief Technology Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,533
-11.53%
|
$60,863
$11.69 P/Share
|
|
Jan 28
2022
|
Don Healey Chief Technology Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+25.0%
|
-
|
|
Jan 28
2022
|
Francesco Galimi SVP & Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,533
-10.06%
|
$60,863
$11.69 P/Share
|
|
Jan 28
2022
|
Francesco Galimi SVP & Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+22.54%
|
-
|
|
Jan 05
2022
|
Aya Jakobovits |
SELL
Open market or private sale
|
Indirect |
4,000
-0.55%
|
$64,000
$16.92 P/Share
|
|
Jan 03
2022
|
Aya Jakobovits |
SELL
Open market or private sale
|
Indirect |
12,000
-1.61%
|
$216,000
$18.02 P/Share
|